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1. | INTR ODUCTION
Correct and consistent use of contraception decreases the risk of unintended pregnancy; yet, 
outdated policies or practices can delay initiation or hinder continuation of contraceptive 
methods. To promote the quality of, and access to, family planning services, WHO created a 
series of evidence-based guidance documents for family planning, known as WHO’s Four 
Cornerstones of Family Planning Guidance (Fig. 1). The Medical eligibility criteria for 
contraceptive use (MEC), first published in 1996,1 provides guidance on the safety of 
various contraceptive methods in users with specific health conditions or characteristics (i.e. 
who can use a contraceptive method safely). The Selected practice recommendations for 
contraceptive use (SPR) is the second cornerstone,2 outlining how to safely and effectively 
use contraceptive methods. These two documents can serve as a reference for policymakers 
and program managers as they develop their own national family planning policies in the 
context of local needs, values, and resources. The two other cornerstone documents—the 
Decision making tool for family planning clients and providers3 and Family planning: a 
global handbook for providers4—provide guidance to healthcare providers for applying 
these recommendations in practice.
Between 2013 and 2014, WHO convened a Guideline Development Group (GDG) to review 
and update the MEC and SPR in line with current evidence. As a result of these meetings, 
the fifth edition of the MEC was published in 2015,5 and the third edition of the SPR will be 
released on December 14, 2016. The purpose of the present report is to describe the methods 
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used to develop the SPR recommendations, research gaps identified during the guideline 
development process, and future directions for the dissemination and implementation of the 
SPR among policymakers and family planning program managers worldwide.
2. | BRIEF HISTORY OF THE WHO SPR
Inconsistencies in recommendations on how to use contraceptive methods could contribute 
to the disparity in contraceptive failure rates reported between “perfect” and “typical” use.2,6 
In 2001, WHO convened the first scientific Working Group—with 33 participants from 16 
countries—to address controversies or inconsistencies in recommendations to maximize the 
effective provision and management of contraception and to minimize and/or manage 
adverse effects that could contribute to discontinuation. The first edition of the SPR2 
included recommendations made in response to 23 specific questions on contraceptive use, 
including when to initiate a contraceptive method, how to be reasonably certain that a 
woman is not pregnant before initiation, the role of necessary examinations or tests before 
initiation, recommended follow-up, how to maintain correct and consistent use, and how to 
address abnormal bleeding from contraceptive use. The Working Group based their 
recommendations on the best available evidence generated from systematic reviews, with 
consideration of the level and applicability of the evidence (i.e. direct or indirect), and relied 
on expert consensus when evidence was lacking.
This is an open access article under the terms of the Creative Commons Attribution-
NonCommercial-NoDerivs License, which permits use and distribution in any medium, 
provided the original work is properly cited, the use is non-commercial and no modifications 
or adaptations are made.
To manage the continuously evolving body of medical evidence, WHO and its collaborators 
launched the Continuous Identification of Research Evidence system in 2002 as an ongoing 
mechanism to identify, evaluate, synthesize, and peer review new evidence pertinent to the 
four cornerstone documents.7 Using the Continuous Identification of Research Evidence 
system, WHO and its partners identified novel and relevant evidence resulting in the creation 
of the second edition of the SPR in 2004,8 an interim guidance in 2008,9 and the latest 
edition in 2016. In addition to maintaining up-to-date recommendations for the contraceptive 
methods in the guidance, WHO strives to include guidance for new contraceptive methods as 
they became available (Table 1).
3. | DEVELOPMENT OF THE THIRD EDITION OF THE SPR
In 2007, WHO’s Director General established the Guidelines Review Committee to ensure 
that WHO guidelines achieve a high methodological quality and are in accordance with the 
requirements described in the WHO handbook for guideline development.10 One of the first 
steps in the updated process was to create groups with different roles to undertake the 
revision. A Secretariat, comprising personnel within WHO headquarters, oversaw the 
guideline development process. The Secretariat provided administrative support, coordinated 
the process for guideline development, and selected participants for the GDG, Evidence 
Secretariat, and external review group. The GDG consisted of technical experts in the 
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contraceptive field, with geographical representation from all WHO regions. The GDG 
determined the scope and content of the guidelines; developed population, intervention, 
comparator and outcome (PICO) questions to guide systematic reviews; and formulated 
recommendations based on the available evidence. Experts in evidence synthesis formed the 
Evidence Secretariat and conducted the systematic reviews, following the pre-determined 
PICO question format. A guideline methodologist with expertise in assessing the quality of 
the evidence using the Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) approach was also part of the Evidence Secretariat. Finally, the 
external review group provided feedback on the draft guidelines from a real-world 
perspective.
The GRADE system offers a process for rating the quality of evidence from systematic 
reviews.11 The GRADE approach considers the study design (i.e. randomized trial or 
observational study), risk of bias, inconsistency across studies, indirectness, data 
imprecision, and publication bias to categorize evidence as high, moderate, low, or very low 
quality. In addition to the GRADE rating, consideration of the values and preferences of 
contraceptive users, the balance of benefits and harms of contraceptive use, and the resource 
implications associated with providing contraceptive services also weighed into the 
determination of the strength of a particular guideline recommendation.
For the third edition of the SPR, the GDG reviewed 19 topics related to five new 
contraceptive methods (Table 2): the two-rod levonorgestrel implant (Sino-implant (II)), 
subcutaneously-administered depot medroxyprogesterone acetate, combined transdermal 
contraceptive patch, combined contraceptive vaginal ring, and ulipristal acetate for 
emergency contraception. Additionally, the GDG considered guidance regarding the 
initiation of regular contraception after emergency contraceptive use. The GDG evaluated 
direct evidence from 15 systematic reviews and extrapolated indirect evidence from 
pharmacologically similar contraceptive methods in the absence of direct evidence. In 
addition to the GRADE evidence profiles, the GDG explicitly considered the values and 
preferences of choice, ease of use, adverse effects, efficacy, and the importance of balancing 
the benefits of preventing unintended pregnancy with potential harms of contraceptive 
method use. The GDG designated a “strong” recommendation as one that could be adopted 
as policy in most situations, whereas a “conditional” recommendation would require 
substantial debate and involvement of various stakeholders before universal implementation 
in all or most settings.10
4. | RESEARCH GAPS
The goal of WHO and its partners is to use the best available evidence to develop SPR 
guidance; however, many recommendations are based on limited or indirect evidence. For 
example, limited information exists on optimal follow-up schedules after contraceptive 
method initiation, and further investigations on the impact of follow-up on contraceptive 
continuation can refine existing recommendations. Additionally, certain recommendations 
are based on indirect evidence from similar contraceptive methods in the absence of direct 
evidence. As an example, recommendations on when to start the combined contraceptive 
patch and contraceptive vaginal ring are derived from indirect data from the combined oral 
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contraceptive pill in view of the similarities in the type and dose of hormone used in 
combined hormonal contraceptive methods. Although these recommendations are likely to 
be scientifically valid, evidence review highlights the relative lack of available data for 
newer contraceptive methods.
Knowledge gaps for future research in contraceptive management are identified with every 
update of the SPR.2,8,9,12,13 Prior SPR editions highlight gaps or key unresolved issues for 
each of the contraceptive methods, such as “Does starting each pill pack on a specific day of 
the week increase consistent, correct and continued use of combined oral contraceptive 
pills?”, “How quickly is protection reliably established by injections of DMPA [depot 
medroxyprogester-one acetate] and NET-EN [norethisterone enantate]?”, and “What are the 
mechanisms underlying progestogen-only injectable-associated bleeding abnormalities and 
how can they best be treated?”.2,8 During the creation of the third edition of the SPR, the 
GDG identified the following research gaps related to the new methods: “How long after the 
start of the menstrual cycle can a woman initiate use of the combined hormonal vaginal ring 
without needing to use a backup method of contraception?”, “Does the timing of return to 
fertility after a DMPA subcutaneous injection differ compared with the timing following a 
DMPA intramuscular injection?”, and “Can Sino-implant (II) be used as an effective method 
of contraception for more than 4 years?”.12 Another research gap is when to start regular 
hormonal contraception after using ulipristal acetate for emergency contraception. New 
evidence suggests that taking ulipristal acetate and progestin-containing contraception in 
close succession could impact effectiveness of both UPA and the regular contraceptive in 
terms of pregnancy prevention.12 Recognition of such research gaps during the SPR revision 
process can serve as a framework to direct future high-quality studies that will further 
inform recommendations, better meet providers’ needs, and improve quality of family 
planning services.
5. | NEXT STEPS AND FUTURE DIRECTIONS
Translating policy into practice is a challenge across all disciplines. To bridge this gap, 
WHO follows the core principles of dissemination, adaptation, implementation, and 
monitoring and evaluation after the creation and publication of a guideline.10 Dissemination 
should be broad and in multiple languages, including online and print publications, peer-
reviewed journals, social media, and regional or scientific meetings. Adaptation takes into 
account specific needs of the country or region. Robust implementation consists of both 
active strategies (e.g. interactive workshops, educational follow-ups, clinical audits, 
reminders, and multifaceted interventions) and passive modalities (e.g. dissemination of 
guidelines in print and electronic form).14 For successful utilization, future guidelines should 
incorporate these effective but underutilized active techniques into detailed, stepwise 
implementation plans. Finally, systems to monitor and evaluate SPR use can determine its 
impact and provide feedback for future implementation strategies.10
In April 2016, WHO convened a Working Group to advise WHO on the preparation of an 
implementation guide for the MEC/SPR, which could enable users of these guides to put 
these principles into action. Since the inception of the SPR, WHO has received few requests 
to translate the SPR into other languages, indicating that the dissemination and uptake of the 
Chen et al. Page 4
Int J Gynaecol Obstet. Author manuscript; available in PMC 2019 June 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
guidance has been limited, especially when compared with the MEC.15 The Working Group 
reviewed strategies for dissemination of the SPR guideline, which currently include 
distribution throughout WHO regional and country offices, coordination with UN partners, 
broadcasting via social media, and promotion of the recommendations at relevant 
conferences and regional meetings. Promoting the SPR and MEC together is important 
because of their inter-related nature; however, the Working Group advised WHO to highlight 
the distinct purpose of the SPR in addressing contraceptive management when disseminating 
both guidelines.
The Working Group proposed a multipronged approach according to three strategies—(1) 
improving guideline usability, (2) assisting countries in adapting the guidelines within their 
local contexts, and (3) turning policy into practice—to structure the implementation guide.
To improve the usability of the updated SPR, the document has been reformatted to be more 
intuitive and user-friendly. For example, the SPR is now organized by contraceptive methods 
rather than by clinical questions, as previous editions had been.
For adaptation, the Working Group strategized ways to help countries to take ownership of 
the SPR, stressing the importance of integrating the guidance into current service delivery 
standards and protocols. Currently, only the USA,16 UK,17 and China have adapted the SPR 
into their national family planning recommendations. Once a country completes adaptation 
of the SPR guidelines, WHO could provide technical support to assist countries to put policy 
into practice through monitoring and evaluation. Strategies to achieve this aim include 
programmatic audits, formation of specialized implementation groups, and creation of a 
repository of implementation prototypes.
Lastly, the Working Group recommended developing a research and documentation plan to 
inform future steps in the implementation process. For example, WHO can take a qualitative 
approach to formally assess a country’s uptake, utilization, and adaptation of contraceptive 
guidelines and tools. Research is important not only in monitoring and evaluating the 
implementation of current guidelines, but also in generating evidence to inform future 
guideline recommendations. The persistent pursuit to close the research gaps identified 
through the SPR guideline update process is paramount to promoting quality in family 
planning care.
WHO has a long-standing history of developing and updating its evidence-based guidance 
on contraceptive method use for a global audience; however, this technical organization 
recognizes the importance of engaging with partners in the guideline development and 
subsequent dissemination, adaptation and implementation processes. Many global partners
—including the Implementing Best Practices Consortium, the International Federation of 
Gynecology and Obstetrics, the International Confederation of Midwives, country-level 
medical societies, and non-governmental organizations—contribute to distributing, 
promoting uptake, and facilitating utilization of the WHO contraceptive guidelines in 
individual countries.
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6. | CONCLUSIONS
As one of the four cornerstones of family planning guidance, the SPR plays a vital part in 
advancing the quality of, and access to, family planning on a global scale. The present report 
has reviewed the history of the SPR and its evolution as both new evidence and novel 
contraceptive methods became available. Additionally, the revision process uncovered 
evidence gaps, highlighting the significant role that research has in informing this 
guideline’s recommendations and continual updates. In view of the relative underuse of the 
SPR as compared with the MEC, the recent update of the SPR has underscored the need and 
importance of applying effective and efficient approaches to promote its dissemination and 
implementation. Findings from high-quality research studies will further strengthen the 
recommendations to ultimately promote the provision of quality family planning care 
worldwide.
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FIGURE 1. 
The four cornerstones of family planning guidance. Abbreviations: MEC, medical eligibility 
criteria for contraceptive use; SPR, selected practice recommendations for contraceptive use. 
Adapted from SPR, 3rd edition, with the permission of WHO.
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y 
or
 c
om
bi
ne
d 
es
tro
ge
n–
pr
og
es
to
ge
n 
EC
Ps
, a
 w
o
m
an
 m
ay
 re
su
m
e 
he
r c
on
tra
ce
pt
iv
e 
m
et
ho
d,
 o
r 
st
ar
t a
ny
 c
on
tra
ce
pt
iv
e 
m
et
ho
d 
im
m
ed
ia
te
ly
N
o 
di
re
ct
 ev
id
en
ce
St
ro
ng
 
 
Fo
llo
w
in
g 
ad
m
in
ist
ra
tio
n 
of
 U
PA
 E
CP
s, 
sh
e 
m
ay
 re
su
m
e 
or
 st
ar
t a
ny
 p
ro
ge
sto
ge
n-
co
nt
ai
ni
ng
 m
et
ho
d 
(ei
the
r C
HC
 or
 pr
og
est
og
en
-
o
n
ly
 c
on
tra
ce
pt
iv
es
) 6
 d 
aft
er 
tak
ing
 U
PA
. S
he
 c
an
 h
av
e 
th
e 
co
pp
er
-
be
ar
in
g 
in
tra
ut
er
in
e 
de
v
ic
e 
in
se
rte
d 
im
m
ed
ia
te
ly
N
o 
di
re
ct
 ev
id
en
ce
St
ro
ng
A
bb
re
v
ia
tio
ns
: L
N
G
, l
ev
o
n
o
rg
es
tre
l; 
SI
(II
), S
ino
-im
pla
nt 
(II
); 
ST
I, s
ex
u
al
ly
 tr
an
sm
itt
ed
 in
fe
ct
io
n;
 D
M
PA
-S
C,
 d
ep
ot
 m
ed
ro
xy
pr
og
es
te
ro
ne
 a
ce
ta
te
 a
dm
in
ist
er
ed
 su
bc
ut
an
eo
us
ly
; C
H
C,
 c
om
bi
ne
d 
ho
rm
on
al
 
co
n
tr
ac
ep
tiv
e;
 C
V
R,
 c
om
bi
ne
d 
co
nt
ra
ce
pt
iv
e 
v
ag
in
al
 ri
ng
; E
CP
,
 
em
er
ge
nc
y 
co
nt
ra
ce
pt
iv
e 
pi
ll;
 U
PA
, u
lip
ris
ta
l a
ce
ta
te
.
a S
tro
ng
 re
co
m
m
en
da
tio
n:
 o
ne
 th
at
 c
an
 b
e 
ad
op
te
d 
as
 p
ol
ic
y 
in
 m
os
t s
itu
at
io
ns
. C
on
di
tio
na
l r
ec
om
m
en
da
tio
n:
 p
ol
ic
y-
m
ak
in
g 
w
ill
 re
qu
ire
 su
bs
ta
nt
ia
l d
eb
at
e 
an
d 
in
v
o
lv
em
en
t o
f v
ar
io
us
 st
ak
eh
ol
de
rs
.
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